Ovarian cancer will kill more women this year than cancer of the uterine corpus and cervix combined. Outcome is stage dependent. At stage IV, the five year survival rate is about 4.5%, but at stage I it may be well over 90%. Overall, regardless of stage, about 30% of women with ovarian cancer will be alive five years after its diagnosis. The fact that changes in treatment over the past two decades have done little to alter these depressing figures has led to a reassessment of our approach to this problem. It has been proposed that earlier diagnosis of the condition will lead to improved patient outcome. Because the disease is asymptomatic in its earliest stages in the majority of cases, this has prompted the search for a reliable screening test that could be used to detect the cancer when it is still confined within the capsule of the ovary. This paper discusses these issues, assesses the different techniques available to screen for ovarian cancer, and comments on possible future developments.